StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Free Report) in a research report report published on Sunday. The firm issued a sell rating on the biotechnology company's stock.
Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a research report on Monday, December 9th. They issued a "buy" rating and a $35.00 price objective on the stock.
Read Our Latest Report on VTVT
vTv Therapeutics Stock Performance
VTVT opened at $18.07 on Friday. The business's fifty day moving average is $15.90 and its two-hundred day moving average is $15.21. The company has a market cap of $57.63 million, a price-to-earnings ratio of -3.99 and a beta of 0.73. vTv Therapeutics has a one year low of $8.22 and a one year high of $30.99.
Institutional Trading of vTv Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in VTVT. FMR LLC acquired a new position in vTv Therapeutics in the third quarter valued at $2,402,000. JPMorgan Chase & Co. acquired a new position in vTv Therapeutics in the fourth quarter valued at $25,000. Finally, Geode Capital Management LLC increased its stake in vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares during the last quarter. 17.51% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Further Reading
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
